alvimopan

Alvimopan is a peripherally acting μ-opioid receptor antagonist used to accelerate the recovery of gastrointestinal function following partial large or small bowel resection with primary anastomosis. It works by competitively binding to μ-opioid receptors in the gastrointestinal tract, thereby blocking the inhibitory effects of endogenous and exogenous opioids on gut motility and secretion. This selective antagonism helps prevent post-operative ileus without affecting centrally mediated opioid analgesia. Alvimopan is approved for short-term use in hospitalized patients and is available only through a restricted program due to potential cardiovascular risks associated with long-term use[1][2][3][5][6].

Brand names

Entereg

Other names

alvimopanalvimopan anhydrous